Latest Asx Companies News

BCAL Diagnostics is expanding access to its Avantect pancreatic and ovarian cancer blood tests across Australia through partnerships with major pathology providers. This move marks a significant step in making early cancer detection more widely available.

Etherstack plc has secured a significant revenue uplift from a scope change in its primary UK government project, adding £1.53 million to its future earnings forecast for FY27.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

Aguia Resources has secured key mining concessions in Brazil, setting the stage for operational licensing and commissioning of its Tres Estradas phosphate mine by April 2026.

Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

Perpetual Equity Investment Company Limited reported a robust net profit increase for the first half of 2026 and maintained its fully franked interim dividend, reinforcing its commitment to reliable shareholder income amid market uncertainties.

Ryder Capital has reported a remarkable 227% increase in comprehensive income for the half-year ending December 2025, alongside a record net tangible asset growth and a new quarterly dividend policy.

Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its Vision-MR Diagnostic Catheter, paving the way for commercial sales in the US electrophysiology market.

Auris Minerals Limited has been queried by the ASX following a sharp rise in its share price and trading volume, with the company denying any undisclosed information behind the surge.